You are here

  • Home
  • Archive
  • Volume 83, Issue 2
  • Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies

Article metrics

Article menu
Spondyloarthritis
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies

 

Online download statistics by month:

Online download statistics by month: October 2023 to August 2024

AbstractFullPdf
Oct 2023211921031554
Nov 2023877880325
Dec 2023754753233
Jan 202412021096496
Feb 2024614616412
Mar 2024639630442
Apr 2024612612346
May 2024498492295
Jun 2024453434256
Jul 2024531527272
Aug 2024535527280
Total883486704911